Use of Osteoporosis Medications after Hospitalization for Hip Fracture: A Cross-national Study

American Journal of Medicine

Volumn 128, Issue 5, 2015, Pages 519-526.e1

  Kim, Seoyoung C ^a   Kim, Mi Sook ^b   Sanfélix Gimeno, Gabriel ^c   Song, Hong Ji ^d   Liu, Jun ^a   Hurtado, Isabel ^c   Peiró, Salvador ^c   Lee, Joongyub ^e   Choi, Nam Kyong ^e   Park, Byung Joo ^b,f   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Seoul National University College of Medicine   (South Korea)

^c Center for Public Health Research   (Spain)

^d Hallym University   (South Korea)

^e Seoul National University Hospital   (South Korea)

^f Korea Institute of Drug Safety and Risk Management   (South Korea)

Author keywords

Adherence; Bisphosphonate; Cohort study; Hip fracture; Osteoporotic fracture

Indexed keywords

ALENDRONIC ACID; CALCITONIN; DENOSUMAB; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADD ON THERAPY; AGED; ARTICLE; BONE DENSITOMETRY; COHORT ANALYSIS; DRUG USE; FEMALE; FRAGILITY FRACTURE; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH PROMOTION; HIP FRACTURE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICARE; MEDICATION COMPLIANCE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT; SECONDARY PREVENTION; SPAIN; UNITED STATES; COMORBIDITY; HIP FRACTURES; OSTEOPOROTIC FRACTURES; SOUTH KOREA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; DIPHOSPHONATES; FEMALE; HIP FRACTURES; HOSPITALIZATION; HUMANS; MALE; OSTEOPOROTIC FRACTURES; REPUBLIC OF KOREA; SECONDARY PREVENTION; SPAIN; UNITED STATES;

EID: 84928978228     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.01.014     Document Type: Article

References (29)

1. M.J. Gardner, K.R. Flik, P. Mooar, and J.M. Lane Improvement in the undertreatment of osteoporosis following hip fracture J Bone Joint Surg Am 84-A 8 2002 1342 1348
2. G.G. Teng, J.R. Curtis, and K.G. Saag Quality health care gaps in osteoporosis: how can patients, providers, and the health system do a better job? Curr Osteoporos Rep 7 1 2009 27 34
3. C.A. Brauer, M. Coca-Perraillon, D.M. Cutler, and A.B. Rosen Incidence and mortality of hip fractures in the United States JAMA 302 14 2009 1573 1579
4. S.E. Roberts, and M.J. Goldacre Time trends and demography of mortality after fractured neck of femur in an English population, 1968-98: database study BMJ 327 7418 2003 771 775
5. C.J. Dy, K.E. McCollister, D.A. Lubarsky, and J.M. Lane An economic evaluation of a systems-based strategy to expedite surgical treatment of hip fractures J Bone Joint Surg Am 93 14 2011 1326 1334
6. M. Nikitovic, W.P. Wodchis, M.D. Krahn, and S.M. Cadarette Direct health-care costs attributed to hip fractures among seniors: a matched cohort study Osteoporos Int 24 2 2013 659 669
7. O. Johnell, and J.A. Kanis An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 17 12 2006 1726 1733
8. K.W. Lyles, C.S. Colon-Emeric, and J.S. Magaziner et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture N Engl J Med 357 2007 nihpa40967
9. L. Bondo, P. Eiken, and B. Abrahamsen Analysis of the association between bisphosphonate treatment survival in Danish hip fracture patients - a nationwide register-based open cohort study Osteoporos Int 24 1 2013 245 252
10. D. Prieto-Alhambra, A. Judge, and N.K. Arden et al. Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial Osteoporos Int 25 1 2014 77 83
11. K.E. Ensrud, D.M. Black, and L. Palermo et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial Arch Intern Med 157 22 1997 2617 2624
12. D.M. Black, S.R. Cummings, and D.B. Karpf et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group Lancet 348 1996 1535 1541
13. G.A. Wells, A. Cranney, and J. Peterson et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women Cochrane Database Syst Rev 1 2008 CD001155
14. National Osteoporosis Foundation. Cinician's guide to prevention and treatment of osteoporosis (2013). Available at: http://nof.org/files/nof/public/content/file/917/upload/481.pdf. Accessed November 5, 2013.
15. Florence R, Allen S, Benedict L, et al. Diagnosis and treatment of osteoporosis (July 2013). Available at: https://www.icsi.org/-asset/vnw0c3/Osteo.pdf. Accessed November 6, 2013.
16. L. Giangregorio, A. Papaioannou, and A. Cranney et al. Fragility fractures and the osteoporosis care gap: an international phenomenon Semin Arthritis Rheum 35 5 2006 293 305
17. V. Rabenda, J. Vanoverloop, and V. Fabri et al. Low incidence of anti-osteoporosis treatment after hip fracture J Bone Joint Surg Am 90 10 2008 2142 2148
18. D.H. Solomon, S.S. Johnston, and N.N. Boytsov et al. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011 J Bone Miner Res 29 2014 1929 1937
19. J.A. Eisman, E.R. Bogoch, and R. Dell et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention J Bone Miner Res 27 2012 2039 2046
20. M. Scaglione, L. Fabbri, and F. Di Rollo et al. The second hip fracture in osteoporotic patients: not only an orthopaedic matter Clin Cases Miner Bone Metab 10 2 2013 124 128
21. C. Colon-Emeric, L. Nordsletten, and S. Olson et al. Association between timing of zoledronic acid infusion and hip fracture healing Osteoporos Int 22 8 2011 2329 2336
22. A. Balasubramanian, L.L. Tosi, and J.M. Lane et al. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009 J Bone Joint Surg Am 96 7 2014 e52
23. D.M. Black, P.D. Delmas, and R. Eastell et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis N Engl J Med 356 18 2007 1809 1822
24. B.G. Durie, M. Katz, and J. Crowley Osteonecrosis of the jaw and bisphosphonates N Engl J Med 353 1 2005 99 102 discussion 99-102
25. L. Gedmintas, D.H. Solomon, and S.C. Kim Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis J Bone Miner Res 28 8 2013 1729 1737
26. W.G. Dixon, and D.H. Solomon Bisphosphonates and esophageal cancer - a pathway through the confusion Nat Rev Rheumatol 7 6 2011 369 372
27. J.R. Curtis, H. Yun, and R. Matthews et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population Arthritis Care Res (Hoboken) 64 7 2012 1054 1060
28. K.R. Olsen, C. Hansen, and B. Abrahamsen Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs - an analysis using national health databases Osteoporos Int 24 10 2013 2639 2647
29. J.S. Sampalis, J.D. Adachi, and E. Rampakakis et al. Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence J Bone Miner Res 27 1 2012 202 210